|
Plant-Based Small Molecules for Treatment of MRSA Infections
Application
Small molecule inhibitor of the accessory gene regulator (agr) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.
Key Benefits
Targeted system is non-essential for S. aureus growth, creating less selective pressure for resistance.
Does not harm beneficial host bacteria.
May potentially be used concomitantly...
Published: 4/23/2020
Inventor(s): Cassandra Quave, Akram Salam, Gina Porras Brenes, James Lyles
|
|
Small Molecule Inhibitor of Akt Activity for Lung Cancer Treatment
Application
Mcl-1/Akt targeting small molecule with strong antitumor activity against lung cancer.
Key Benefits
Novel molecule.
Novel target presents new path to lung cancer treatment.
Potentially extend survival rate of lung cancer patients.
Market Summary
Lung cancer is the number one leading cause of death among cancer patients. Patients...
Published: 4/17/2020
Inventor(s): Xingming Deng
|
|
Reprogramming Human Urine Stem Cells into Vascular Tissue
Application
System to generate vascular progenitor cells within naturally constructed (or formed) biomatrices from urine cells.
Key Benefits
Nearly limitless supply of source cells.
Non-invasive method for harvesting source cells.
Efficient endothelial cell generation with fewer steps and faster generation time than current standard for differentiating...
Published: 1/23/2020
Inventor(s): Young-Sup Yoon, Young-Doug Sohn, Sang-Ho Lee
|
|
Small Molecule for Treatment-Resistant Lung Cancer
Application
Small molecule agonist for treating cancers involving KRAS mutations.
Key Benefits
Specifically targets mutant KRAS in non-small-cell lung carcinoma (NSCLC).
Selective for mutant KRAS lung cancer cells over normal cells.
Non-toxic to normal cells.
Market Summary
Lung cancer is the leading cause of cancer death in the US. Lung cancer...
Published: 1/14/2020
Inventor(s): Xingming Deng
|
|
Subunit-Selective NMDAR Antagonists for Treatment of Neurological Disorders
Application
GluN2C/2D selective inhibitors that modulate N-methyl-D-aspartic acid receptors (NMDAR) in a subunit-selective manner for treatment of neurological disorders.
Key Benefits
Specifically targets NMDARs that contain the GluN2C/2D subunit.
Higher potency and efficacy compared to previously reported GluN2C/2D-selective modulators.
Market...
Published: 1/10/2020
Inventor(s): Yao Jing, Stephen Traynelis, Dennis Liotta
|
|
Antibacterial Treatment for Gum Disease
Application
Small molecules that inhibit oral bacteria growth to treat gum disease and prevent tooth decay.
Key Benefits
Inhibits S. mutans biofilm formation.
Reduces the number of bacteria by working in a bactericidal, as opposed to bacteriostatic, manner.
Market Summary
Periodontitis is a gum infection in which gums become inflamed due to...
Published: 12/2/2019
Inventor(s): William (Bill) Wuest, Amy Solinski, Marisa Kozlowski, Young Eun Lee, Thomas Paniak, Cristian Ochoa
|
|
TGFβR3-based Biomaterial to Treat Bone Damage
Application
PEG-MAL (Poly(ethylene glycol) methyl ether maleimide) polymer gel composition containing soluble TGFβ3R or embedded with modified TGFβ3R over-expressing cells for bone growth and repair therapy.
Key Benefits
Targets a non-BMP2 signaling pathway to improve BMP signaling.
•Avoids complications associated with BMP2.
Market...
Published: 9/20/2019
Inventor(s): Steven Goudy
|
|
Subunit-Selective Modulator for Treatment of Neurological Disorders
Application
Subunit-selective GluN2C and GluN2D positive allosteric modulators of N-methyl-D-aspartic acid receptors (NMDAR) for treatment of neurological disorders.
Key Benefits
Specifically targets GluN2C/D subunits for positive modulation of NMDAR activity.
Higher potency compared to non-selective modulators.
Improved drug-like properties...
Published: 8/26/2019
Inventor(s): Matthew Epplin, David Menaldino, Stephen Traynelis, Dennis Liotta
|
|
Small Molecule Inhibitors of Mcl-1 as Anti-Cancer Agent
Application
Myeloid cell leukemia 1 (Mcl-1) inhibitor to enhance DNA replication stress sensitivity for cancer therapy.
Key Benefits
Inhibits DNA repair in cancer cells.
Used in combination with existing cancer therapy.
Market Summary
Chemoresistance occurs when cancer cells develop resistance to chemotherapy drugs, and appearance of chemoresistance...
Published: 6/24/2019
Inventor(s): Xingming Deng, Guo Chen, Abu Syed Md Anisuzzaman
|
|
Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma
Application
Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax.
Key Benefits
Co-therapy increases MM sensitivity to venetoclax treatment.
Identifies patients who will respond to venetoclax therapy.
Market Summary
Multiple Myeloma (MM) is a cancer of plasma cells responsible for making antibody...
Published: 6/18/2019
Inventor(s): Malathy (mala) Shanmugam, Richa Bajpai
|
Emory UniversityOffice of Technology Transfer